Diabetes medication explained

Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors.

Diabetes mellitus type 1 is a disease caused by the lack of insulin. Thus, Insulin is the main treatment agent for type 1 and is typically administered via subcutaneous injection.

Diabetes mellitus type 2 is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.

Several drug classes are indicated for use in type 2 diabetes and are often used in combination. Therapeutic combinations may include several insulin isoforms or varying classes of oral antihyperglycemic agents. As of 2020, 23 unique antihyperglycemic drug combinations were approved by the FDA.[1] The first triple combination of oral anti-diabetics was approved in 2019, consisting of metformin, saxagliptin, and dapagliflozin. Another triple combination approval for metformin, linagliptin, and empagliflozin followed in 2020.[1]

__TOC__

Mechanisms of action

Diabetes medications have four main mechanisms of action:

Insulin

See main article: Insulin (medication). Insulin is usually given subcutaneously, either by injections or by an insulin pump. In acute care settings, insulin may also be given intravenously. Insulins are typically characterized by the rate at which they are metabolized by the body, yielding different peak times and durations of action.[3] Faster-acting insulins peak quickly and are subsequently metabolized, while longer-acting insulins tend to have extended peak times and remain active in the body for more significant periods.[4]

Examples of rapid-acting insulins (peak at ~1 hour) are:

Examples of short-acting insulins (peak 2–4 hours) are:

Examples of intermediate-acting insulins (peak 4–10 hours) are:

Examples of long-acting insulins (duration 24 hours, often without peak) are:

Insulin degludec is sometimes classed separately as an "ultra-long" acting insulin due to its duration of action of about 42 hours, compared with 24 hours for most other long-acting insulin preparations.

As a systematic review of studies comparing insulin detemir, insulin glargine, insulin degludec and NPH insulin did not show any clear benefits or serious adverse effects for any particular form of insulin for nocturnal hypoglycemia, severe hypoglycemia, glycated hemoglobin A1c, non-fatal myocardial infarction/stroke, health-related quality of life or all-cause mortality.[5] The same review did not find any differences in effects of using these insulin analogues between adults and children.

Most oral anti-diabetic agents are contraindicated in pregnancy, in which case insulin is preferred.

Insulin is not administered by other routes, although this has been studied. An inhaled form was briefly licensed but was subsequently withdrawn.[6]

Sensitizers

Insulin sensitizers address the core problem in type 2 diabetes – insulin resistance.

Biguanides

See main article: Biguanide. Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery, including skeletal muscle. Although it must be used with caution in patients with impaired liver or kidney function, Metformin, a biguanide, has become the most commonly used agent for type 2 diabetes in children and teenagers. Among common diabetic drugs, Metformin is the only widely used oral drug that does not cause weight gain.[7]

Typical reduction in glycated hemoglobin (A1C) values for Metformin is 1.5–2.0%

Metformin is a first-line medication used for treatment of type 2 diabetes. It is generally prescribed at initial diagnosis in conjunction with exercise and weight loss, as opposed to the past, where it was prescribed after diet and exercise had failed. There is an immediate-release as well as an extended-release formulation, typically reserved for patients experiencing gastrointestinal side-effects. It is also available in combination with other oral diabetic medications.

Thiazolidinediones

See main article: Thiazolidinedione. Thiazolidinediones (TZDs), also known as "glitazones," bind to PPARγ, peroxisome proliferator activated receptor γ, a type of nuclear regulatory protein involved in the transcription of genes that regulate glucose and fat metabolism. These PPARs act on peroxisome proliferator responsive elements (PPRE).[11] The PPREs influence insulin-sensitive genes, which enhance production of mRNAs of insulin-dependent enzymes. The final result is better use of glucose by the cells. These drugs also enhance PPAR-α activity and hence lead to a rise in HDL and some larger components of LDL.[12]

Typical reductions in glycated hemoglobin (A1C) values are 1.5–2.0%. Some examples are:

Multiple retrospective studies have resulted in a concern about rosiglitazone's safety, although it is established that the group, as a whole, has beneficial effects on diabetes. The greatest concern is an increase in the number of severe cardiac events in patients taking it. The ADOPT study showed that initial therapy with drugs of this type may prevent the progression of disease,[16] as did the DREAM trial.[17] The American Association of Clinical Endocrinologists (AACE), which provides clinical practice guidelines for management of diabetes, retains thiazolidinediones as recommended first, second, or third line agents for type 2 diabetes mellitus, as of their 2019 executive summary, over sulfonylureas and α-glucosidase inhibitors. However, they are less preferred than GLP-1 agonists or SGLT2 inhibitors, especially in patients with cardiovascular disease (which liraglutide, empagliflozin, and canagliflozin are all FDA approved to treat).[18]

Concerns about the safety of rosiglitazone arose when a retrospective meta-analysis was published in the New England Journal of Medicine.[19] There have been a significant number of publications since then, and a Food and Drug Administration panel[20] voted, with some controversy, 20:3 that available studies "supported a signal of harm", but voted 22:1 to keep the drug on the market. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate the issue, and several other reports have failed to conclude the controversy. This weak evidence for adverse effects has reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control.[21] Safety studies are continuing.

In contrast, at least one large prospective study, PROactive 05, has shown that pioglitazone may decrease the overall incidence of cardiac events in people with type 2 diabetes who have already had a heart attack.[22]

LYN Kinase Activators

The LYN kinase activator Tolimidone has been reported to potentiate insulin signaling in a manner that is distinct from the glitazones.[23] The compound has demonstrated positive results in a Phase 2a clinical study involving 130 diabetic subjects.[24]

Secretagogues

Secretagogues are drugs that increase output from a gland, in the case of insulin from the pancreas.

Sulfonylureas

See main article: Sulfonylurea. Sulfonylureas were the first widely used oral anti-hyperglycemic medications. They are insulin secretagogues, triggering insulin release by inhibiting the KATP channel of the pancreatic beta cells. Eight types of these pills have been marketed in North America, but not all remain available. The "second-generation" sulfonylureas are now more commonly used. They are more effective than first-generation drugs and have fewer side-effects. All may cause weight gain.

Current clinical practice guidelines from the AACE rate sulfonylureas (as well as glinides) below all other classes of antidiabetic drugs in terms of suggested use as first, second, or third line agents - this includes Bromocriptine, the bile acid sequestrant Colesevelam, α-glucosidase inhibitors, Thiazolidinediones (glitazones), and DPP-4 inhibitors (gliptins). The low cost of most sulfonylureas, however, especially when considering their significant efficacy in blood glucose reduction, tends to keep them as a more feasible option in many patients - neither SGLT2 inhibitors nor GLP-1 agonists, the classes most favored by the AACE guidelines after metformin, are currently available as generics.

Sulfonylureas bind strongly to plasma proteins. Sulfonylureas are useful only in type 2 diabetes, as they work by stimulating endogenous release of insulin. They work best with patients over 40 years old who have had diabetes mellitus for under ten years. They cannot be used with type 1 diabetes, or diabetes of pregnancy. They can be safely used with metformin or glitazones. The primary side-effect is hypoglycemia, which appears to happen more commonly with sulfonylureas than with other treatments.[25]

A Cochrane systematic review from 2011 showed that treatment with Sulfonylureas did not improve control of glucose levels more than insulin at 3 nor 12 months of treatment.[26] This same review actually found evidence that treatment with Sulfonylureas could lead to earlier insulin dependence, with 30% of cases requiring insulin at 2 years. When studies measured fasting C-peptide, no intervention influenced its concentration, but insulin maintained concentration better compared to Sulphonylurea. Still, it is important to highlight that the studies available to be included in this review presented considerable flaws in quality and design.

Typical reductions in glycated hemoglobin (A1C) values for second-generation sulfonylureas are 1.0–2.0%.

Meglitinides

See main article: Meglitinide. Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues." They act on the same potassium channels as sulfonylureas, but at a different binding site.[27] By closing the potassium channels of the pancreatic beta cells, they open the calcium channels, thereby enhancing insulin secretion.[28]

They are taken with or shortly before meals to boost the insulin response to each meal. If a meal is skipped, the medication is also skipped.

Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.

Adverse reactions include weight gain and hypoglycemia.

Alpha-glucosidase inhibitors

See main article: Alpha-glucosidase inhibitor. Alpha-glucosidase inhibitors are a class of diabetes drugs, however, they are technically not hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, such that glucose from the starch enters the bloodstream at a slower rate, and can be matched more effectively by an impaired insulin response or sensitivity. These agents are effective by themselves only in the earliest stages of impaired glucose tolerance, but can be helpful in combination with other agents in type 2 diabetes.

Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.

These medications are rarely used in the United States because of the severity of their side-effects (flatulence and bloating). They are more commonly prescribed in Europe. They do have the potential to cause weight loss by lowering the amount of sugar metabolized.

Peptide analogs

Injectable incretin mimetics

Incretins are also insulin secretagogues. The two main candidate molecules that fulfill criteria for being an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (glucose-dependent insulinotropic peptide, GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

Injectable glucagon-like peptide analogs and agonists

Glucagon-like peptide (GLP) agonists bind to a membrane GLP receptor.[28] As a consequence, insulin release from the pancreatic beta cells is increased. Endogenous GLP has a half-life of only a few minutes, thus an analogue of GLP would not be practical. As of 2019, the AACE lists GLP-1 agonists, along with SGLT2 inhibitors, as the most preferred anti-diabetic agents after metformin. Liraglutide in particular may be considered first-line in diabetic patients with cardiovascular disease, as it has received FDA approval for reduction of risk of major adverse cardiovascular events in patients with type 2 diabetes.[29] In a 2011 Cochrane review, GLP-1 agonists showed approximately a 1% reduction in HbA1c when compared to placebo. GLP-1 agonists also show improvement of beta-cell function, but this effect does not last after treatment is stopped. Due to shorter duration of studies, this review did not allow for long-term positiver or negative effects to be assessed.

These agents may also cause a decrease in gastric motility, responsible for the common side-effect of nausea, which tends to subside with time.

Dipeptidyl peptidase-4 inhibitors

See main article: Dipeptidyl peptidase-4 inhibitor. GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general dipeptidyl peptidase-4 (DPP-4) inhibitors were weight-neutral and are associated with increased risk for infection and headache. Both classes appear to present an alternative to other antidiabetic drugs. However, weight gain and/or hypoglycemia have been observed when dipeptidyl peptidase-4 inhibitors were used with sulfonylureas; effects on long-term health and morbidity rates are still unknown.[39]

DPP-4 inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by DPP-4.

Examples are:

DPP-4 inhibitors lowered hemoglobin A1C values by 0.74%, comparable to other antidiabetic drugs.[40]

A result in one RCT comprising 206 patients aged 65 or older (mean baseline HgbA1c of 7.8%) receiving either 50 or 100 mg/d of sitagliptin was shown to reduce HbA1c by 0.7% (combined result of both doses).[41] A combined result of 5 RCTs enlisting a total of 279 patients aged 65 or older (mean baseline HbA1c of 8%) receiving 5 mg/d of saxagliptin was shown to reduce HbA1c by 0.73%.[42] A combined result of 5 RCTs enlisting a total of 238 patients aged 65 or older (mean baseline HbA1c of 8.6%) receiving 100 mg/d of vildagliptin was shown to reduce HbA1c by 1.2%.[43] Another set of 6 combined RCTs involving alogliptin (approved by FDA in 2013) was shown to reduce HbA1c by 0.73% in 455 patients aged 65 or older who received 12.5 or 25 mg/d of the medication.[44]

Injectable amylin analogues

Amylin agonist analogues slow gastric emptying and suppress glucagon. They have all the incretins actions except stimulation of insulin secretion., pramlintide is the only clinically available amylin analogue. Like insulin, it is administered by subcutaneous injection. The most frequent and severe adverse effect of pramlintide is nausea, which occurs mostly at the beginning of treatment and gradually reduces. Typical reductions in A1C values are 0.5–1.0%.[45]

SGLT2 inhibitors

See main article: Gliflozin. SGLT2 inhibitors block the sodium-glucose linked transporter 2 proteins in renal tubules of nephrons in kidneys, reabsorption of glucose in into the renal tubules, promoting excretion of glucose in the urine. This causes both mild weight loss, and a mild reduction in blood sugar levels with little risk of hypoglycemia.[46] Oral preparations may be available alone or in combination with other agents.[47] Along with GLP-1 agonists, they are considered preferred second or third agents for type 2 diabetics sub-optimally controlled with metformin alone, according to most recent clinical practice guidelines. Because they are taken by mouth, rather than injected (like GLP-1 agonists), patients who are injection-averse may prefer these agents over the former. They may be considered first line in diabetic patients with cardiovascular disease, especially heart failure, as these medications have been shown to reduce the risk of hospitalization in patients with such comorbidities.[48] Because they are not available as generic medications, however, cost may limit their feasibility for many patients. Furthermore, there has been growing evidence that the effectiveness and safety of this drug class could depend on genetic variability of the patients.[49]

Examples include:

The side effects of SGLT2 inhibitors are derived directly from their mechanism of action; these include an increased risk of: ketoacidosis, urinary tract infections, candidal vulvovaginitis, and hypoglycemia.[50]

Comparison

The following table compares some common anti-diabetic agents, generalizing classes, although there may be substantial variation in individual drugs of each class. When the table makes a comparison such as "lower risk" or "more convenient" the comparison is with the other drugs on the table.

Comparison of anti-diabetic medication[51] [52]
Drug classMechanism of action[53] AdvantagesDisadvantages
Sulfonylureas (glyburide, glimepiride, glipizide)Stimulating insulin release by pancreatic beta cells by inhibiting the KATP channel
  • Inexpensive
  • Fast onset of action
  • No effect on blood pressure
  • No detrimental effect on low-density lipoprotein
  • Lower risk of gastrointestinal side effects than metformin
  • Convenient dosing
  • Cause an average of 2–5 kg weight gain
  • Increase the risk of hypoglycemia
  • Glyburide increases risk of hypoglycemia slightly more compared to glimepiride and glipizide
MetforminActs on the liver to reduce gluconeogenesis and causes a decrease in insulin resistance via increasing AMPK signalling.
  • Associated with weight loss
  • Lower risk of hypoglycemia compared to other antidiabetics
  • Decreases low-density lipoprotein
  • Decreases triglycerides
  • No effect on blood pressure
  • Lowered all-cause mortality in diabetics
  • Inexpensive
Alpha-glucosidase inhibitors (acarbose, miglitol, voglibose)Inhibit carbohydrate digestion in the small intestine by inhibiting enzymes that break down polysaccharides
  • Slightly lower risk of hypoglycemia compared to sulfonylureas
  • Associated with modest weight loss
  • Decreases triglycerides
  • No detrimental effect on cholesterol
  • Less effective than most other diabetes pills in lowering glycated hemoglobin
  • Increased risk of GI side effects than other diabetes pills except metformin
  • Inconvenient dosing
Thiazolidinediones (Pioglitazone, Rosiglitazone)Reduce insulin resistance by activating PPAR-γ in fat and muscle
  • Lower the risk of hypoglycemia
  • May slightly increase high-density lipoprotein
  • Rosiglitazone linked to decreased triglycerides
  • Convenient dosing
  • Increase the risk of heart failure
  • Cause an average of 2–5 kg weight gain
  • Are associated with a higher risk of edema, anemia and bone fractures
  • Can increase low-density lipoprotein
  • Rosiglitazone has been linked to increased triglycerides and an increased risk of a heart attack
  • Pioglitazone has been linked to an increased risk of bladder cancer
  • Have a slower onset of action
  • Require monitoring for hepatotoxicity
  • Expensive
SGLT2 inhibitors

Generics

Many anti-diabetes drugs are available as generics. These include:[54]

No generics are available for dipeptidyl peptidase-4 inhibitors (Onglyza), the glifozins, the incretins and various combinations. Sitagliptin patent expired in July 2022, leading to launch of generic sitagliptin[55] brands . This lowered the cost of therapy for type 2 diabetes using sitagliptin .

Alternative Medicine

The effect of Ayurvedic treatments has been researched, however due to methodological flaws of relevant studies and research, it has not been possible to draw conclusions regarding efficacy of these treatments and there is insufficient evidence to recommend them.[56]

Further reading

Notes and References

  1. Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, Schiöth HB . Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. Front Pharmacol . 12 . 4119 . January 2022 . 35126141 . 8807560 . 10.3389/fphar.2021.807548 . free.
  2. Web site: OVERVIEW OF DIABETES DRUGS . diabetes daily.
  3. Book: Powers AC . Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J . Anthony Fauci . . 2011 . McGraw-Hill . 978-0071748896 . 18th . Diabetes Mellitus.
  4. Book: Donner T, Sarkar S . Insulin – Pharmacology, Therapeutic Regimens, and Principles of Intensive Insulin Therapy . 2000 . http://www.ncbi.nlm.nih.gov/books/NBK278938/ . Endotext . Feingold KR, Anawalt B, Boyce A, Chrousos G . MDText.com, Inc. . 25905175 . 2019-11-16 .
  5. Hemmingsen B, Metzendorf MI, Richter B . (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus . The Cochrane Database of Systematic Reviews . 3 . 4 . CD013498 . March 2021 . 33662147 . 8094220 . 10.1002/14651858.cd013498.pub2 .
  6. Mastrandrea LD . Inhaled insulin: overview of a novel route of insulin administration . Vascular Health and Risk Management . 6 . 47–58 . March 2010 . 20234779 . 10.2147/VHRM.S6098 . free .
  7. 2024-01-04 . Erratum: Metformin: Current knowledge . Journal of Research in Medical Sciences . en . 29 . 1 . 6 . 10.4103/JRMS.JRMS_62_24 . free . 38524744 . 10956562 . 1735-1995.
  8. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA . Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review . BMJ . 335 . 7618 . 497 . September 2007 . 17761999 . 1971204 . 10.1136/bmj.39314.620174.80 .
  9. Fimognari FL, Pastorelli R, Incalzi RA . Phenformin-induced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis) . Diabetes Care . 29 . 4 . 950–951 . April 2006 . 16567854 . 10.2337/diacare.29.04.06.dc06-0012 . live . free . mdy-all . https://archive.today/20121209052027/http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=16567854 . December 9, 2012 .
  10. Verdonck LF, Sangster B, van Heijst AN, de Groot G, Maes RA . Buformin concentrations in a case of fatal lactic acidosis . Diabetologia . 20 . 1 . 45–46 . 1981 . 7202882 . 10.1007/BF01789112 . free .
  11. Web site: diabetesinsulinPPAR . www.healthvalue.net . live . https://web.archive.org/web/20160303204348/http://www.healthvalue.net/diabetesinsulinPPAR.html . March 3, 2016 . May 6, 2018 . mdy-all.
  12. Kersten S . Peroxisome proliferator activated receptors and lipoprotein metabolism . PPAR Research . 2008 . 1 . 132960 . 2008-01-02 . 18288277 . 10.1155/2008/132960 . free . Chinetti G .
  13. European Medicines Agency, "European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim", EMA, 23 September 2009
  14. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE . Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials . JAMA . 298 . 10 . 1180–1188 . September 2007 . 17848652 . 10.1001/jama.298.10.1180 .
  15. News: Hinterthuer A . Retired Drugs: Failed Blockbusters, Homicidal Tampering, Fatal Oversights . October 1, 2008 . 2009-06-21 . live . https://web.archive.org/web/20081204050525/http://www.wired.com/medtech/drugs/multimedia/2008/10/gallery_retired_drugs?slide=6&slideView=6 . December 4, 2008 . . mdy-all.
  16. Web site: Expert Column – A Diabetes Outcome Progression Trial (ADOPT) . Haffner SM . 2007 . Medscape . 2007-09-21.
  17. Web site: DREAM: Rosiglitazone Effective in Preventing Diabetes . Gagnon L . 24 October 2006 . Medscape . live . https://web.archive.org/web/20081202225351/http://www.medscape.com/viewarticle/546503 . December 2, 2008 . 2007-09-21 . mdy-all.
  18. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE . Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary . Endocrine Practice . 25 . 1 . 69–100 . January 2019 . 30742570 . 10.4158/cs-2018-0535 . free .
  19. Nissen SE, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes . The New England Journal of Medicine . 356 . 24 . 2457–2471 . June 2007 . 17517853 . 10.1056/NEJMoa072761 . free .
  20. Web site: Wood S . FDA Advisory Panels Acknowledge Signal of Risk With Rosiglitazone, but Stop Short of Recommending Its Withdrawal . Heartwire . 2007-07-31 . 2007-09-21 . live . https://web.archive.org/web/20140318013618/http://www.medscape.com/viewarticle/560709 . March 18, 2014 . mdy-all .
  21. Ajjan RA, Grant PJ . The cardiovascular safety of rosiglitazone . Expert Opinion on Drug Safety . 7 . 4 . 367–376 . July 2008 . 18613801 . 10.1517/14740338.7.4.367 . 73109231 .
  22. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM . The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study . Journal of the American College of Cardiology . 49 . 17 . 1772–1780 . May 2007 . 17466227 . 10.1016/j.jacc.2006.12.048 . free .
  23. Müller G, Wied S, Frick W . Cross talk of pp125(FAK) and pp59(Lyn) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes . Molecular and Cellular Biology . 20 . 13 . 4708–4723 . July 2000 . 10848597 . 85892 . 10.1128/mcb.20.13.4708-4723.2000 .
  24. Web site: Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study. businesswire.com. June 13, 2016. May 6, 2018. live. https://web.archive.org/web/20170812162052/http://www.businesswire.com/news/home/20160613005028/en/Melior-Pharmaceuticals-Announces-Positive-Phase-2A-Results. August 12, 2017. mdy-all.
  25. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A . Glucagon-like peptide analogues for type 2 diabetes mellitus . The Cochrane Database of Systematic Reviews . 10 . CD006423 . October 2011 . 2011 . 21975753 . 6486297 . 10.1002/14651858.cd006423.pub2 .
  26. Brophy S, Davies H, Mannan S, Brunt H, Williams R . Interventions for latent autoimmune diabetes (LADA) in adults . The Cochrane Database of Systematic Reviews . 9 . CD006165 . September 2011 . 2011 . 21901702 . 6486159 . 10.1002/14651858.cd006165.pub3 .
  27. Rendell M . Advances in diabetes for the millennium: drug therapy of type 2 diabetes . MedGenMed . 6 . 3 Suppl . 9 . September 2004 . 15647714 . 1474831 .
  28. Web site: Helping the pancreas produce insulin . 2007-09-21 . HealthValue. https://web.archive.org/web/20070927043729/http://www.healthvalue.net/diabetespancreasbeta.html. September 27, 2007 . live.
  29. Web site: Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients. Drugs.com. en. 2019-11-16.
  30. Briones M, Bajaj M . Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus . Expert Opinion on Pharmacotherapy . 7 . 8 . 1055–1064 . June 2006 . 16722815 . 10.1517/14656566.7.8.1055 . 43740629 .
  31. Gallwitz B . Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data . International Journal of Clinical Practice . 60 . 12 . 1654–1661 . December 2006 . 17109672 . 10.1111/j.1742-1241.2006.01196.x . 8800490 . free .
  32. Cvetković RS, Plosker GL . Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) . Drugs . 67 . 6 . 935–954 . 2007 . 17428109 . 10.2165/00003495-200767060-00008 . 195691202 .
  33. Web site: Novo Nordisk Files for Regulatory Approval of Liraglutide in Both the US and Europe . 2018-01-23 . live . https://web.archive.org/web/20171215054200/https://www.drugs.com/nda/liraglutide_080530.html . December 15, 2017 . mdy-all . May 2008
  34. Web site: Liraglutide Provides Significantly Better Glucose Control Than Insulin Glargine in Phase 3 Study . 2010-02-09 . live . https://web.archive.org/web/20100723042509/http://www.medicalnewstoday.com/articles/74913.php . July 23, 2010 . mdy-all . "Liraglutide Provides Significantly Better Glucose Control Than Insulin Glargine In Phase 3 Study" June 2007
  35. Web site: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes . 2010-02-09 . live . https://web.archive.org/web/20090205233559/http://www.medicalnewstoday.com/articles/110349.php . February 5, 2009 . mdy-all . "Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, And Blood Pressure In Patients With Type 2 Diabetes" June 2008
  36. Web site: Liraglutide – Next-Generation Antidiabetic Medication . 2010-02-09 . live . https://web.archive.org/web/20100618110150/http://www.drugdevelopment-technology.com/projects/liraglutide/ . June 18, 2010 . mdy-all .
  37. Web site: Quarterly R&D; Update - Novo Nordisk A/S . 2010-02-09 . dead . https://web.archive.org/web/20100109101501/http://www.novonordisk.com/science/about_rd/quarterly_rd_update.asp . January 9, 2010 . Oct 2008 Inc results of LEAD 6 extension
  38. Web site: Novo Nordisk Receives US Approval for Victoza(R) (Liraglutide) for the Treatment of Type 2 Diabetes . 2010-02-09 . live . https://web.archive.org/web/20100129215943/https://money.cnn.com/news/newsfeeds/articles/marketwire/0580389.htm . January 29, 2010 . mdy-all . January 2009
  39. National Prescribing Service . RADAR . Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes mellitus . 1 August 2010 . 7 March 2021.
  40. Amori RE, Lau J, Pittas AG . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis . JAMA . 298 . 2 . 194–206 . July 2007 . 17622601 . 10.1001/jama.298.2.194 .
  41. Barzilei N, Mahoney EM, Guo H . Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM. Diabetes. 2009. 58. 587.
  42. Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J . Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus . Current Medical Research and Opinion . 27 . 4 . 863–869 . April 2011 . 21323504 . 10.1185/03007995.2011.554532 . 206965817 .
  43. Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S . Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy . Diabetes Care . 30 . 12 . 3017–3022 . December 2007 . 17878242 . 10.2337/dc07-1188 . free .
  44. Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q . Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies . Journal of the American Geriatrics Society . 57 . 11 . 2011–2019 . November 2009 . 19793357 . 10.1111/j.1532-5415.2009.02484.x . 28683917 .
  45. Ryan G, Briscoe TA, Jobe L . Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes . Drug Design, Development and Therapy . 2 . 203–214 . February 2009 . 19920907 . 10.2147/DDDT.S3225 . free .
  46. Dietrich E, Powell J, Taylor JR . Canagliflozin: a novel treatment option for type 2 diabetes . Drug Design, Development and Therapy . 7 . 1399–1408 . November 2013 . 24285921 . 3840773 . 10.2147/DDDT.S48937 . free .
  47. Web site: Drug Safety and Availability - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors . Center for Drug Evaluation and Research. www.fda.gov. en. 2017-08-26. live. https://web.archive.org/web/20161129094121/http://www.fda.gov/Drugs/DrugSafety/ucm446852.htm. November 29, 2016. mdy-all.
  48. Web site: UpToDate. www.uptodate.com. 2019-11-16.
  49. https://www.bjbms.org/ojs/index.php/bjbms/article/view/5646 Imamovic Kadric S, Kulo Cesic A, Dujic T. Pharmacogenetics of new classes of antidiabetic drugs. Bosn J of Basic Med Sci. 2021.
  50. News: SGLT2 Inhibitors (Gliflozins) – Drugs, Suitability, Benefits & Side Effects. 2017-08-26. live. https://web.archive.org/web/20170827050028/http://www.diabetes.co.uk/diabetes-medication/sglt2-inhibitors.html. August 27, 2017. mdy-all.
  51. Cambon-Thomsen A, Rial-Sebbag E, Knoppers BM . Trends in ethical and legal frameworks for the use of human biobanks . The European Respiratory Journal . 30 . 2 . 373–382 . August 2007 . 17666560 . 10.1183/09031936.00165006 . free . adapted from table 2, which includes a list of issues
  52. Consumer Reports Health Best Buy Drugs . Consumer Reports . The Oral Diabetes Drugs: Treating Type 2 Diabetes . . Best Buy Drugs . 20 . September 18, 2012 . live . https://web.archive.org/web/20130227145458/http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/DiabetesUpdate-FINAL-Feb09.pdf . February 27, 2013 . mdy-all ., which is citing
    • Oral Diabetes Medications for Adults With Type 2 Diabetes. An Update. Comparative Effectiveness Review. March 2011. 27. 28 November 2012. Agency for Healthcare Research and Quality. Agency for Healthcare Research and Quality. dead. https://web.archive.org/web/20130927121129/http://effectivehealthcare.ahrq.gov/ehc/products/155/645/Oral%20Diabetes_ExSumm%20%282%29.pdf. September 27, 2013. mdy-all.
    • Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S . Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations . Annals of Internal Medicine . 154 . 9 . 602–613 . May 2011 . 21403054 . 3733115 . 10.7326/0003-4819-154-9-201105030-00336 .
  53. Table entries taken from page 185 in: Book: Elizabeth D Agabegi . Agabegi, Steven S. . Step-Up to Medicine (Step-Up Series) . Lippincott Williams & Wilkins . Hagerstwon, MD . 2008 . 978-0-7817-7153-5 . registration .
  54. Web site: The Oral Diabetes Drugs Treating Type 2 Diabetes Comparing Effectiveness, Safety, and Price . July 17, 2013 . live . https://web.archive.org/web/20130615083100/http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/DiabetesUpdate-FINAL-Feb09.pdf . June 15, 2013 . mdy-all .
  55. Web site: 31 January 2024 . Sitagliptin Generic Alternatives . 31 January 2024 . www.sastimedic.com.
  56. Sridharan K, Mohan R, Ramaratnam S, Panneerselvam D . Ayurvedic treatments for diabetes mellitus . The Cochrane Database of Systematic Reviews . 12 . CD008288 . December 2011 . 22161426 . 3718571 . 10.1002/14651858.CD008288.pub2 . Cochrane Metabolic and Endocrine Disorders Group .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Diabetes medication".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.